Effectiveness and safety of ustekinumab in pediatric Crohn's disease: Results of the REALITI study - PubMed
4 hours ago
- #ustekinumab
- #pediatric
- #Crohn's disease
- The REALITI study evaluated the effectiveness and safety of ustekinumab in pediatric and young adult patients with Crohn's disease (CD) using real-world data from the ImproveCareNow (ICN) registry.
- At Week 52, clinical remission was achieved by 47.3% of pediatric patients and 44.8% of young adults, with corticosteroid-free clinical remission rates of 41.3% and 39.1%, respectively.
- Among patients with moderately-to-severely active CD, clinical remission rates were lower, at 36.9% for pediatric patients and 34.3% for young adults, with corticosteroid-free remission rates of 31.5% and 28.6%, respectively.
- Ustekinumab was well tolerated, with no new safety signals identified during the study.
- The study concluded that ustekinumab's effectiveness and safety profiles were similar in both pediatric and young adult patients with CD over 52 weeks.